Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06408376

Physiological Umbilical Cord Clamping in Patients With Congenital Diaphragmatic Hernia. Clinical Trial

Congenital diaphragmatic hernia (CDH) is a malformation that affects 1 in every 3000 newborns. The diaphragm does not complete its closure during embryogenesis, which allows the abdominal organs to herniate into the thoracic cavity altering lung development. The lungs of patients with CDH are small, with a decreased surface area for gas exchange and developmental impair of the pulmonary vasculature, resulting in respiratory failure and pulmonary hypertension shortly after birth. When clamping the umbilical cord, a large part of the preload is abruptly excluded, generating an increase in vascular resistance, which in turn increase the afterload, resulting in a decrease in cardiac output. The output is restored by decreasing vascular resistance in pulmonary circuit after lung aeration upon receiving the preload of the right atrium, increasing pulmonary flow and thus sustaining the preload of the left ventricle. If pulmonary aeration occurs before clamping the umbilical cord, the pulmonary blood flow increases before placenta flow is lost, thus avoiding a decrease in cardiac output. This modality has been called physiological base cord clamping (PFC). The hypothesis is that PFC once ventilation has been established could prevent hypoxia and improve cardiac output in newborns with CDH and secondarily improve their hemodynamic parameters, stabilizing gas exchange and pulmonary hypertension during the first 24 hours of birth.

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

  • Type of study: Randomized clinical trial
  • Primary objective: To establish the effectiveness of PFC in reducing hypoxia and improving cardiac output compared to immediate postintubation clamping in newborns with CDH. To establish the safety and feasibility of PFC after pulmonary recruitment achieved post intubation.
  • Secondary objectives: describe the evolution of patients with CDH 24 hours after birth under pre-established conditions. Relate prenatal indices to the subsequent evolution of these patients. Describe maternal evolution and postpartum complications.
  • Population: Patients who attend the Fetal Diagnosis and Treatment program of Garrahan Children's Hospital and undergo prenatal diagnosis of CDH are possible candidates. The study will be carried out in the Neonatal Intensive Care Unit of said hospital.
  • Scope of the study: Garrahan Children's Hospital is a level 3 B pediatric hospital and national referral center located in Autonomous City of Buenos Aires, Argentina. Center that receives neonates with CDH referred from all over the country as well as from other countries in the region and carries out the relevant training for equal reception.
  • Block randomization: will be carried out on the same day, 2 hours before entering the delivery room
  • Intervention: Immediately after birth, the newborn will be placed on a mobile table, made to received these patients in the delivery room, at the level of the mother's womb, leaving the umbilical cord intact, intubated and gently ventilated (positive inspiration pressure (PIM) 15/25 - positive end expiratory pressure (PEEP)4 - fraction of inspired oxygen inspired oxygen fraction (FiO2) 50%), until saturation >85% and heart rate (HR) >100 or 10 timed minutes pass, whichever occurs first, the umbilical cord will be clamped and continued with the usual reception steps in accordance with the unit´s CDH reception protocol.
  • Sample size: To calculate the sample size, a prevalence of hemodynamic alterations of 60% was considered in the first 24 hours of life of patients with CDH, following unit statistics and the aforementioned bibliography. The estimated sample size with a relative reduction of 50%: reduction from 60% to 30% of hemodynamic alterations - Power of 80% - Two-tailed test - alpha 5%. 40 patients required in each branch.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Prenatal diagnosis of congenital diaphragmatic hernia
  • gestational age >34 weeks
  • Informed consent signed by the patient's parents

Exclusion criteria

  • Multiple gestation
  • Major malformation or fetal genetic anomaly diagnosed in the prenatal stage
  • Emergency cesarean section or maternal condition that prevents the approach
  • Lack of informed consent

Treatment and study plan

Physiological cord clamping

Procedure

Immediately after birth, the newborn with prenatal diagnosis of CDH will be placed on a mobile table, made to receive these patients in the delivery room, at the level of the mother's womb, leaving the umbilical cord intact and intubated. The patient will be gently ventilated (PIM 15/25 - PEEP 4 - Fio2 50%), until saturation >85% and HR>100 or 10 timed minutes have elapsed, whichever occurs first, the umbilical cord will be clamped.

Primary outcomes

  1. Hemodynamic deterioration in the first 24 hours of life

    Time frame: 24 hours of life

    Hemodynamic deterioration in the first 24 hours of life (meeting 3 of 4 of the following criteria or entry to extracorporeal membrane oxygenation (ECMO) or Death).

    • Pre/post ductal saturation difference >10%
    • Oxygenation index (IO) >20
    • mean arterial pressure < Percentile 50 or inotrope requirement
    • Lactic acid >3 mmol/l
  2. complete delivery according group

    Time frame: delivery

    Complete the protocol in the delivery room pre-established according to randomization (yes/no)

Secondary outcomes

  1. Gestational age at diagnosis

    Time frame: 1st day of life

    Gestational age at diagnosis of CDH in weeks

  2. Lung heart rate index observed/expected LHR O/E

    Time frame: from 26 to 32 weeks of gestational age

    lung heart rate index observed/expected (LHR O/E)

  3. liver in thorax

    Time frame: from 26 to 32 weeks of gestational age

    liver in thorax (yes/no) and %

  4. stomach herniation

    Time frame: from 26 to 32 weeks of gestational age

    stomach herniation (yes/no) and %

  5. lung volumen

    Time frame: from 26 to 32 weeks of gestational age

    lung volumen in RMI

  6. Mcgoon

    Time frame: from 26 to 32 weeks of gestational age

    Mcgoon Index in fetal echocardiogram

  7. maternal hematocrit

    Time frame: 1 day before delivery

    maternal hematocrit in gr/dl

  8. Intubation time

    Time frame: From delivery to intubation

    Time to intubation (minutes, seconds)

  9. Cord clamping time

    Time frame: from delivery to cord clamping

    Cord clamping time (minutes, seconds)

  10. Advance resuscitation need on delivery room

    Time frame: from delivery to 30 minutes of life

    Requirement for advanced resuscitation (yes/no) (compressions, drugs, hypothermia)

  11. Time to reach heart rate (HR) >100

    Time frame: from delivery to 30 minutes of life

    Time to reach HR >100 (minutes, seconds)

  12. Time to reach saturation (SAT) >85%

    Time frame: from delivery to 30 minutes of life

    Time to reach SAT >85% (minutes, seconds)

  13. Cord PH value

    Time frame: inmediatly after cord clampping

    cord ph value

  14. Cord lactic acid value

    Time frame: inmediatly after cord clampping

    cord lactic acid value in mmol/l

  15. saturation at 10 minutes

    Time frame: 10 minutes of life

    pre and post ductal saturation %

  16. Arterial pressure at 10 minutes

    Time frame: 10 minutes of life

    mean arterial tension in mmhg

  17. placenta abruption

    Time frame: 30 minutes of life

    Time for placental abruption (minutes, seconds)

  18. Mother arterial tension after delivery

    Time frame: 10 minutes after delivery

    mothers arterial mean tension after delivery in mmhg

  19. Uterotonic use

    Time frame: 30 minutes after delivery

    uterotonics use on mothers after delivery (yes/no)

  20. Evolution of patient Blood preassure (BP)

    Time frame: 2 - 4 hours and 24 hours of life

    Blood pressure in mmhg

  21. Evolution of patient inotropes required

    Time frame: 2 - 4 hours and 24 hours of life

    Inotrope requirement (yes/no)

  22. Inhaled nitric oxide (NOi) requirement

    Time frame: 2 - 4 hours and 24 hours of life

    NOi requirement (yes/no)

  23. ventilation requirements on the first day

    Time frame: 2 - 4 hours and 24 hours of life

    Ventilatory mode / mean airway pressure (MAP)/ FIo2 %

  24. Oxygenation on the first day

    Time frame: 2 - 4 hours and 24 hours of life

    Partial arterial pressure of oxygen (PaO2) mmhg

  25. Oxygenation index (OI) on the first day

    Time frame: 2 - 4 hours and 24 hours of life

    OI

  26. near-infrared spectroscopy (Nirs) on the first day

    Time frame: 2 - 4 hours and 24 hours of life

    Cerebral and somatic NIRS

  27. B natriuretic peptide (BNP) on the first day

    Time frame: 24 hours of life

    B natriuretic peptide (BNP)

  28. PH value on the first day

    Time frame: 6 and 24 hours of life

    echocardiographic pulmonary hypertension PH (<50% of systemic pressure, between 50-80% of systemic pressure, between 80 and 100% of systemic pressure, systemic, suprasystemic)

  29. cardiac malformations

    Time frame: 6 hours of life

    cardiac malformation (yes/no)

  30. Mortality

    Time frame: through study completion, an average of 1 year

    Mortality (yes/no)

  31. Admission to ECMO

    Time frame: through study completion, an average of 1 year

    Admission to ECMO after the first 24 hours (yes/no)

Other outcomes

  1. maternal age

    Time frame: through study completion, an average of 1 year

    maternal age during pregnancy

  2. maternal history

    Time frame: through study completion, an average of 1 year

    maternal pathological history during pregnancy (yes/no)

  3. baby weight

    Time frame: 30 minutes of life

    Weight in grams

  4. Patent ductus arteriosus (PAD) on the first day (size)

    Time frame: 6 and 24 hours of life

    Patent ductus arteriosus (PAD): size in milimeters

  5. Patent ductus arteriosus (PAD) on the first day (gradient)

    Time frame: 6 and 24 hours of life

    Patent ductus arteriosus (PAD): gradient

  6. Patent ductus arteriosus (PAD) on the first day (shunt direction)

    Time frame: 6 and 24 hours of life

    Patent ductus arteriosus (PAD): shunt direction

  7. Patent foramen ovale (PFO) on the first day (shunt direction)

    Time frame: 6 and 24 hours of life

    Patent foramen ovale (PFO): shunt direction.

  8. Right ventricle (RV) on the first day diameter

    Time frame: 6 and 24 hours of life

    Right ventricle (RV): RV diameter in milimeters

  9. Right ventricle (RV) on the first day TAPSE

    Time frame: 6 and 24 hours of life

    Right ventricle (RV): TAPSE

  10. Tricuspide Insufitienty

    Time frame: 6 and 24 hours of life

    tricuspide insufitienty

  11. Right ventricle funtion

    Time frame: 6 and 24 hours of life

    Right ventricle global disfuntion : no, mild, moderate or severe

  12. Left ventricle (LV) on the first day (eccentricity index)

    Time frame: 6 and 24 hours of life

    Left ventricle (LV): eccentricity index

  13. Left ventricle (LV) on the first day (ejection fraction)

    Time frame: 6 and 24 hours of life

    Left ventricle (LV): ejection fraction (EF)

  14. Left ventricle (LV) on the first day global funtion

    Time frame: 6 and 24 hours of life

    Left ventricle (LV) global disfuntion : no, global disfuntion : no, mild, moderate or severe

  15. Interventricular septum (IS) on the first day

    Time frame: 6 and 24 hours of life

    Interventricular septum: configuration

  16. Pulmonary hypertation grade on the first day

    Time frame: 6 and 24 hours of life

    Pulmonary hypertation: no, mild, moderate or severe

  17. Associated malformations

    Time frame: 24 hours of life

    Associated malformations (yes/no), which

  18. Chromosomopathy or genetic alteration

    Time frame: through study completion, an average of 1 year

    Chromosomopathy or genetic alteration (yes/no), which

  19. Hyperbilirubinemia

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

    Hyperbilirubinemia requiring phototherapy or exchange transfusion (yes/no)

  20. Early sepsis

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

    Early sepsis (yes/no)

  21. Omphalitis

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

    Omphalitis (yes/no)

  22. CDH surgery

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

    CDH surgery (yes/no), days of life

  23. Surgical classification

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

    Surgical classification of CDH (a-b-c-d)

  24. Days in neonatal intensive care unit (NICU)

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

    Days in NICU

Study contacts

Contact information is provided by the study sponsor or research team.

Maria T Mazzucchelli

CONTACT

[email protected]

+5491149170437

Mariela Jozefkowicz

CONTACT

[email protected]

+5491164646270

Sponsors and collaborators

Lead sponsor

Hospital JP Garrahan

Other Gov

Registry information

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
May 10, 2024
Registry last updated
May 10, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.